Study sets ‘benchmark’ for TB treatment


The findings of a new study have been hailed by medical experts as an advancement for tuberculosis control, particularly multidrug-resistant TB.

The NExT study has revealed that a novel all-oral six-month treatment regime is as, if not more, effective for multidrug-resistant tuberculosis (MDR-TB) when compared to the World Health Organisation (WHO) approved nine‑month injectable-based regimen...

This article is reserved for HeraldLIVE subscribers.

A subscription gives you full digital access to all our content.

Already subscribed? Simply sign in below.

Already registered on DispatchLIVE, BusinessLIVE, TimesLIVE or SowetanLIVE? Sign in with the same details.

Questions or problems? Email or call 0860 52 52 00.